Report Overview
The Antimicrobial Susceptibility Testing Market is set to reach USD 12.03 billion in 2031, growing at a CAGR of 8.8 % from USD 5.63 billion in 2026.
Highlights:
- 1Automated AST systems dominate the global market.
- 2Rising antimicrobial resistance continues to accelerate market demand.
- 3Rapid molecular susceptibility testing is the fastest-growing technology segment.
- 4Hospital microbiology laboratories remain the largest end users.
Antimicrobial susceptibility testing is a critical component of clinical microbiology that determines the effectiveness of antimicrobial agents against specific bacterial and fungal pathogens. AST enables clinicians to select targeted therapies, minimize antimicrobial resistance, and improve infection management. Modern AST solutions include automated analyzers, molecular diagnostics, broth microdilution systems, and digital laboratory software that deliver rapid, standardized, and highly accurate results. Growing global initiatives to combat antimicrobial resistance are further strengthening demand for advanced susceptibility testing technologies.
Market Dynamics
Market Drivers
The increasing prevalence of multidrug-resistant pathogens is driving demand for rapid and accurate antimicrobial susceptibility testing. Healthcare providers are adopting advanced AST systems to support targeted antibiotic therapy and improve patient outcomes.
The rising number of bacterial, fungal, and healthcare-associated infections has increased the need for timely pathogen identification and susceptibility testing. This trend is expanding the utilization of AST across hospitals, diagnostic laboratories, and public health institutions.
Clinical laboratories are investing in automated AST platforms to improve workflow efficiency, reduce turnaround time, and enhance diagnostic accuracy. Laboratory automation is becoming a key growth driver, particularly in high-volume healthcare facilities.
National antimicrobial stewardship programs and global initiatives led by organizations such as the WHO and CDC are encouraging wider implementation of antimicrobial susceptibility testing, strengthening market growth worldwide.
Market Restraints
Automated susceptibility testing instruments and molecular diagnostic platforms require significant capital investment, limiting adoption among small and medium-sized laboratories.
Operation of advanced microbiology analyzers requires trained personnel with expertise in microbiology, molecular diagnostics, and laboratory automation, creating workforce challenges in many regions.
Strict regulatory requirements for in vitro diagnostic devices increase product development timelines and commercialization costs, delaying market entry for innovative technologies.
Many low- and middle-income countries lack adequate laboratory infrastructure, funding, and diagnostic capacity, restricting widespread implementation of advanced AST technologies.
Market Opportunities
Increasing demand for PCR-based and molecular resistance detection technologies presents significant opportunities for manufacturers developing rapid antimicrobial susceptibility testing solutions.
AI-powered result interpretation, automated workflow management, and digital microbiology platforms are creating opportunities to improve laboratory productivity and diagnostic precision.
Development of portable and decentralized AST platforms capable of delivering rapid results at the point of care offers substantial growth potential, particularly in emergency medicine and resource-limited settings.
The expanding use of antimicrobial susceptibility testing in pharmaceutical research, clinical trials, drug development, and antimicrobial resistance surveillance is creating new commercial opportunities for AST manufacturers and diagnostic service providers.
Government Regulations
Regulatory Authority | Regulation/Guideline | Region | Impact on the Antimicrobial Susceptibility Testing Market |
U.S. Food and Drug Administration (FDA) | 21 CFR Part 866 – Immunology and Microbiology Devices | United States | Regulates the approval, performance, labeling, and commercialization of antimicrobial susceptibility testing (AST) systems, reagents, and related in vitro diagnostic devices. |
European Commission | In Vitro Diagnostic Regulation (IVDR) (EU) 2017/746 | European Union | Establishes requirements for clinical performance, CE marking, quality management, and post-market surveillance of AST products marketed in the EU. |
Clinical and Laboratory Standards Institute (CLSI) | CLSI M100 – Performance Standards for Antimicrobial Susceptibility Testing | Global | Provides globally recognized standards for antimicrobial susceptibility testing methods, breakpoint interpretation, and quality control used by clinical microbiology laboratories. |
International Organization for Standardization (ISO) | ISO 13485:2016 – Medical Devices Quality Management Systems | Global | Defines quality management system requirements for the design, manufacture, and distribution of antimicrobial susceptibility testing instruments, reagents, and software. |
Market Segmentation
By Product
The reagents and consumables segment accounts for the largest share of the antimicrobial susceptibility testing market because AST procedures require continuous use of susceptibility panels, culture media, antimicrobial disks, broth reagents, quality control materials, and testing kits. Instruments generate significant capital revenue through automated AST analyzers and integrated microbiology platforms, while software adoption continues increasing as laboratories implement digital workflow management, automated result interpretation, antimicrobial stewardship support, and laboratory information management systems (LIMS). Increasing laboratory testing volumes are expected to sustain strong growth across all product categories throughout the forecast period.
By Method
Automated susceptibility testing represents the leading method due to its ability to provide standardized, reproducible, and rapid antimicrobial susceptibility results with minimal manual intervention. Large hospitals and reference laboratories increasingly prefer automated systems to improve laboratory efficiency and reduce turnaround times. Manual susceptibility testing continues to maintain an important role in small laboratories, resource-limited healthcare settings, and confirmatory testing because of its lower implementation costs and established clinical reliability. Growing laboratory automation is expected to further strengthen adoption of automated AST platforms during the forecast period.
By Technology
Broth microdilution remains the reference standard for antimicrobial susceptibility testing because it provides highly accurate minimum inhibitory concentration (MIC) determination and supports standardized clinical decision-making. Disk diffusion continues to be widely used owing to its simplicity, affordability, and extensive clinical acceptance. Gradient diffusion methods provide quantitative MIC values while maintaining operational flexibility for routine laboratories. Rapid molecular methods are experiencing the fastest growth because they enable early detection of antimicrobial resistance genes and significantly reduce diagnostic turnaround times. Continuous innovation in molecular diagnostics and automated microbiology systems is expected to drive future technological advancements across the AST market.
Regional Analysis
North America
North America dominates the antimicrobial susceptibility testing market due to the widespread implementation of antimicrobial stewardship programs, advanced clinical microbiology laboratories, strong regulatory oversight, and high adoption of automated AST systems. Increasing antimicrobial resistance surveillance initiatives continue driving investments in rapid susceptibility testing technologies.
Europe
Europe represents a mature AST market supported by strong healthcare infrastructure, comprehensive antimicrobial resistance monitoring programs, and widespread implementation of laboratory automation. The region continues emphasizing standardized susceptibility testing and responsible antibiotic utilization.
Asia Pacific
Asia Pacific is expected to witness the fastest market growth owing to rising infectious disease burden, increasing antimicrobial resistance, expanding healthcare infrastructure, and growing government investments in laboratory modernization. Adoption of automated AST technologies continues increasing across major healthcare markets.
South America
Latin America is experiencing steady market growth as hospitals and diagnostic laboratories strengthen infectious disease management capabilities. Government initiatives targeting antimicrobial resistance and improving laboratory capacity continue supporting adoption of susceptibility testing technologies.
Middle East & Africa
The Middle East & Africa market is expanding gradually due to increasing healthcare investments, laboratory modernization programs, and growing awareness of antimicrobial resistance. GCC countries remain the primary adopters of advanced AST platforms within the region.
Rest of the World
Emerging healthcare markets continue investing in microbiology laboratories and infectious disease surveillance programs, creating additional growth opportunities for antimicrobial susceptibility testing technologies over the long term.
Regulatory Landscape
The antimicrobial susceptibility testing market is regulated under stringent global frameworks governing in vitro diagnostic (IVD) medical devices. Regulatory agencies require comprehensive analytical validation, clinical performance evaluation, quality management systems, and post-market surveillance before commercialization of AST instruments, reagents, and software. Compliance with regulations such as the U.S. FDA requirements, European IVDR (EU 2017/746), China's NMPA regulations, and internationally recognized standards including ISO 13485, ISO 15189, and CLSI guidelines ensures diagnostic accuracy, laboratory quality, and patient safety. Increasing regulatory emphasis on rapid antimicrobial resistance detection, software validation, cybersecurity, and laboratory automation continues shaping product development across the AST industry.
Pipeline Analysis
The antimicrobial susceptibility testing pipeline is focused on developing faster, more accurate, and highly automated diagnostic technologies capable of supporting antimicrobial stewardship and combating antimicrobial resistance. Current innovations include next-generation automated AST analyzers, rapid phenotypic susceptibility testing platforms, multiplex molecular resistance detection assays, AI-assisted result interpretation software, digital microbiology systems, and integrated antimicrobial susceptibility testing workflows. Companies are also expanding technologies capable of detecting resistance mechanisms directly from positive blood cultures while reducing turnaround times from days to hours. Continued advances in laboratory automation, artificial intelligence, molecular diagnostics, and cloud-connected microbiology platforms are expected to significantly improve diagnostic efficiency and clinical decision-making.
Company Analysis
bioMérieux
bioMérieux is a global leader in antimicrobial susceptibility testing through its VITEK platform, automated microbiology systems, and antimicrobial stewardship solutions. The company continues expanding its microbiology portfolio through continuous innovation.
Becton, Dickinson and Company (BD)
BD provides comprehensive microbiology laboratory solutions, including automated identification and susceptibility testing systems, specimen management technologies, and antimicrobial resistance surveillance platforms.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific offers microbiology reagents, molecular diagnostics, sequencing technologies, laboratory automation solutions, and antimicrobial susceptibility testing products supporting clinical laboratories worldwide.
Danaher Corporation
Danaher, through Beckman Coulter, develops laboratory automation and diagnostic workflow solutions that enhance microbiology laboratory productivity and susceptibility testing efficiency.
Bruker Corporation
Bruker continues expanding its MALDI-TOF-based microbiology solutions by integrating rapid organism identification with antimicrobial susceptibility testing workflows.
QIAGEN N.V.
QIAGEN specializes in molecular diagnostics, syndromic testing, and antimicrobial resistance gene detection technologies supporting rapid susceptibility testing.
Bio-Rad Laboratories, Inc.
Bio-Rad develops molecular diagnostic assays, quality control products, and laboratory systems supporting infectious disease diagnostics and antimicrobial resistance detection.
Accelerate Diagnostics, Inc.
Accelerate Diagnostics focuses on rapid pathogen identification and phenotypic antimicrobial susceptibility testing technologies that significantly reduce time-to-result.
Beckman Coulter, Inc.
Beckman Coulter provides laboratory automation, microbiology workflow optimization, and diagnostic solutions supporting efficient antimicrobial susceptibility testing.
Merlin Diagnostika GmbH
Merlin Diagnostika develops specialized antimicrobial susceptibility testing products, culture media, and diagnostic solutions serving clinical microbiology laboratories.
Key Developments
May 2026: bioMérieux expanded its VITEK automated microbiology platform with enhanced antimicrobial susceptibility testing capabilities supporting faster clinical decision-making.
March 2026: BD introduced workflow improvements for automated microbiology laboratories aimed at strengthening antimicrobial stewardship initiatives.
January 2026: Thermo Fisher Scientific expanded its clinical microbiology portfolio through new molecular diagnostic solutions for antimicrobial resistance detection.
October 2025: Accelerate Diagnostics advanced rapid phenotypic antimicrobial susceptibility testing technologies designed to reduce diagnostic turnaround times.
August 2025: Bruker enhanced its MALDI-TOF microbiology workflow by expanding integration with antimicrobial susceptibility testing applications.
Strategic Outlook
The antimicrobial susceptibility testing market is expected to experience sustained growth through 2035 as healthcare systems intensify efforts to combat antimicrobial resistance and improve antibiotic stewardship. Automated microbiology platforms, rapid molecular diagnostics, AI-enabled laboratory workflows, and integrated susceptibility testing solutions will continue driving market innovation. Companies capable of delivering rapid, accurate, and scalable AST technologies while supporting laboratory automation and precision infectious disease management are expected to strengthen their competitive positions in the evolving global diagnostics market.
Antimicrobial Susceptibility Testing Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2024 | USD 5.63 billion |
| Total Market Size in 2034 | USD 12.03 billion |
| Forecast Unit | USD Billion |
| Growth Rate | 8.8 % |
| Study Period | 2019 to 2034 |
| Historical Data | 2019 to 2022 |
| Base Year | 2023 |
| Forecast Period | 2024 – 2034 |
| Segmentation | Product, Method, End User, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|
Market Segmentation
Product
Method
End User
Geography
Geographical Segmentation
North America, South America, Europe, Middle East and Africa, Asia Pacific
Table of Contents
1. EXECUTIVE SUMMARY
1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations
2. RESEARCH METHODOLOGY
2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations
3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET OVERVIEW, SIZE & FORECAST
3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021–2025)
3.6 Market Forecast (2026–2035)
3.7 Antimicrobial Resistance (AMR) Burden Analysis
3.8 Testing Volume Analysis
3.9 Laboratory Workflow Analysis
3.10 Clinical Significance of Antimicrobial Susceptibility Testing
4. MARKET DYNAMICS
4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges
5. INDUSTRY LANDSCAPE
5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape
6. INNOVATION LANDSCAPE
6.1 Emerging Technologies
6.2 Product Innovation
6.3 Diagnostic Pipeline Analysis
6.4 Automation in Antimicrobial Susceptibility Testing
6.5 Artificial Intelligence and Data Analytics Integration
6.6 Digital Microbiology and Laboratory Informatics
6.7 Technology Roadmap
7. REGULATORY LANDSCAPE
7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements
8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET LANDSCAPE ANALYSIS
8.1 Analysis by Product Type
8.1.1 Instruments
8.1.2 Reagents & Consumables
8.1.3 Software
8.2 Analysis by Technology Platform
8.2.1 Automated AST Systems
8.2.2 Manual AST Methods
8.2.3 Molecular AST Methods
8.2.4 Broth Microdilution
8.2.5 Disk Diffusion
8.2.6 Gradient Diffusion (E-test)
8.3 Analysis by Sample Type
8.3.1 Blood
8.3.2 Urine
8.3.3 Respiratory Samples
8.3.4 Wound Samples
8.3.5 Other Clinical Samples
8.4 Analysis by Application
8.4.1 Clinical Diagnostics
8.4.2 Pharmaceutical Research
8.4.3 Food Safety Testing
8.4.4 Veterinary Diagnostics
9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENT ANALYSIS (2021–2035)
9.1 By Product
9.1.1 Instruments
9.1.2 Reagents & Consumables
9.1.3 Software
9.2 By Method
9.2.1 Automated Susceptibility Testing
9.2.2 Manual Susceptibility Testing
9.3 By Technology
9.3.1 Broth Microdilution
9.3.2 Disk Diffusion
9.3.3 Gradient Diffusion
9.3.4 Rapid Molecular Methods
9.3.5 Other Technologies
9.4 By Application
9.4.1 Clinical Diagnostics
9.4.2 Drug Discovery & Development
9.4.3 Epidemiological Surveillance
9.4.4 Food & Beverage Testing
9.4.5 Veterinary Diagnostics
9.5 By End User
9.5.1 Hospitals
9.5.2 Diagnostic Laboratories
9.5.3 Pharmaceutical & Biotechnology Companies
9.5.4 Academic & Research Institutes
9.5.5 Food Testing Laboratories
9.5.6 Veterinary Laboratories
10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET GEOGRAPHICAL ANALYSIS (2021–2035)
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa
11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET COUNTRY ANALYSIS (2021–2035)
11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 Japan
11.10 China
11.11 India
11.12 South Korea
11.13 Australia
11.14 Brazil
11.15 Mexico
11.16 Saudi Arabia
11.17 South Africa
12. COMPETITIVE LANDSCAPE
12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches
13. COMPANY PROFILES
13.1 bioMérieux
13.1.1 Company Overview
13.1.2 Financials
13.1.3 Product Portfolio
13.1.4 Recent Developments
13.2 Becton, Dickinson and Company
13.2.1 Company Overview
13.2.2 Financials
13.2.3 Product Portfolio
13.2.4 Recent Developments
13.3 Thermo Fisher Scientific Inc.
13.3.1 Company Overview
13.3.2 Financials
13.3.3 Product Portfolio
13.3.4 Recent Developments
13.4 Danaher Corporation
13.4.1 Company Overview
13.4.2 Financials
13.4.3 Product Portfolio
13.4.4 Recent Developments
13.5 Bruker Corporation
13.5.1 Company Overview
13.5.2 Financials
13.5.3 Product Portfolio
13.5.4 Recent Developments
13.6 QIAGEN N.V.
13.6.1 Company Overview
13.6.2 Financials
13.6.3 Product Portfolio
13.6.4 Recent Developments
13.7 Bio-Rad Laboratories, Inc.
13.7.1 Company Overview
13.7.2 Financials
13.7.3 Product Portfolio
13.7.4 Recent Developments
13.8 Accelerate Diagnostics, Inc.
13.8.1 Company Overview
13.8.2 Financials
13.8.3 Product Portfolio
13.8.4 Recent Developments
13.9 Beckman Coulter, Inc.
13.9.1 Company Overview
13.9.2 Financials
13.9.3 Product Portfolio
13.9.4 Recent Developments
13.10 Merlin Diagnostika GmbH
13.10.1 Company Overview
13.10.2 Financials
13.10.3 Product Portfolio
13.10.4 Recent Developments
13.11 Hardy Diagnostics
13.11.1 Company Overview
13.11.2 Financials
13.11.3 Product Portfolio
13.11.4 Recent Developments
13.12 Liofilchem S.r.l.
13.12.1 Company Overview
13.12.2 Financials
13.12.3 Product Portfolio
13.12.4 Recent Developments
13.13 HiMedia Laboratories Pvt. Ltd.
13.13.1 Company Overview
13.13.2 Financials
13.13.3 Product Portfolio
13.13.4 Recent Developments
13.14 Creative Diagnostics
13.14.1 Company Overview
13.14.2 Financials
13.14.3 Product Portfolio
13.14.4 Recent Developments
13.15 Mast Group Ltd.
13.15.1 Company Overview
13.15.2 Financials
13.15.3 Product Portfolio
13.15.4 Recent Developments
14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET COMMERCIAL FORECAST ANALYSIS
14.1 Automated AST Systems
14.2 Manual AST Systems
14.3 Broth Microdilution Products
14.4 Disk Diffusion Products
14.5 Gradient Diffusion Products
14.6 Molecular AST Platforms
14.7 AST Reagents & Consumables
14.8 Laboratory Software Solutions
15. INVESTMENT & FUNDING ANALYSIS
15.1 Venture Capital Trends
15.2 Government Funding
15.3 R&D Investments
16. FUTURE OUTLOOK
16.1 Key Growth Opportunities
16.2 Future Industry Trends
Navigate
Trusted by the world's leading organizations
